clairop

Can You Live Without UC Medication? The Evidence

Most people with ulcerative colitis relapse when maintenance treatment stops. What the withdrawal studies show for 5-ASA, azathioprine and biologics.

Clairop Team24 min read

Photo: Vitaly Gariev / Unsplash

The short answer

For most people with ulcerative colitis, no: stopping maintenance treatment is followed by relapse far more often than staying on it. A few people in long, documented remission stop under supervision, with calprotectin and scope checks. That is a decision for your IBD team, never a trial to run alone.

Trying to find your triggers? Clairop logs meals, symptoms and stool in seconds on iPhone, then flags foods your gut reacts to, including delayed reactions.

Get it on the App Store

For most people with ulcerative colitis (UC), the answer to "can I live without medication?" is no, not safely. UC is a chronic immune-driven inflammation of the colon lining, and the studies that follow people after treatment is withdrawn show relapse far more often than when it continues. A small group in long, documented remission do step treatment down, but only under supervision, with stool and scope checks. This guide sets out what the evidence shows, drug class by drug class, and why it is a decision for your IBD team and not a personal experiment.

If you came here because you are tired of taking tablets, worried about side effects, struggling with cost, or simply feel well, that is a completely understandable place to be. Nothing below is a recommendation to stop, start, switch or change any medicine. It is a plain-English map of the research so that you can walk into the conversation with your gastroenterologist better informed. Where evidence is thin, we say so.

Can you live without medication with ulcerative colitis?

For most people, no: relapse is much more likely when maintenance treatment stops than when it continues. In a Cochrane review of 44 trials, 37% of people taking oral mesalamine relapsed within 6 to 12 months, compared with 55% on placebo (relative risk 0.68, high-certainty evidence) (Murray 2020). Some people do stay well with little or no treatment, but they are the exception and are usually closely monitored. Related: can you stop Crohn's medication in remission?

The honest framing is a spectrum. At one end are people with extensive or moderate-to-severe disease whose remission depends on their treatment. At the other are a few people with mild disease who responded quickly, had a long documented remission and now have a plan that includes regular testing and an agreed route back onto treatment. Most people sit in between, which is why generic advice, including the confident "never stop" and "you can manage with diet" lines both found online, fails so many readers.

A useful way to think about it: the question is not "medication or no medication" but "what is the least treatment that keeps the lining quiet, proven by tests and not by how I feel?" That is a question only your IBD team can answer, and it is answered with data over time.

Do you need to stay on ulcerative colitis meds forever?

Usually you stay on some form of treatment, though not necessarily the same drug or intensity for life. NIDDK states that people with UC typically need lifelong treatment with medicines unless they have surgery to remove the colon and rectum (NIDDK). That is a statement about the typical case, and it leaves room for individual variation.

The evidence on how much maintenance mesalamine lowers relapse risk is summarized in does mesalamine work for ulcerative colitis.

Two things sit behind "forever". First, UC is a relapsing condition. Population cohorts that follow newly diagnosed people for years show that a large majority have at least one relapse, even though many have long quiet stretches, as we set out in is ulcerative colitis for life. Second, remission on treatment and remission off treatment are different states. When a medicine is working, the quiet you feel is partly the drug.

Treatment can also move in either direction. People sometimes step up because a drug has stopped working (see what it means when a biologic stops working). Occasionally, after prolonged documented remission, a team will discuss stepping down. Neither is a failure. The thread running through both is monitoring. For the case for and against staying on one, see are biologics worth it for ulcerative colitis?.

What happens if you stop taking mesalamine (5-ASA)?

Stopping 5-ASA on its own is linked to a higher relapse risk, but the picture changes if you also take a stronger drug. A 2026 systematic review and meta-analysis of 29 studies found that discontinuing oral 5-ASA monotherapy was associated with a 60% increase in relapse risk in UC (relative risk 1.60, 95% CI 1.25 to 2.05, low-certainty evidence). Stopping rectal 5-ASA carried a relative risk of 2.03 (95% CI 1.58 to 2.61, moderate certainty) (Arzivian 2026).

In the same review, people who were also on immunomodulators or biologics did not show a clear increase in relapse when 5-ASA was withdrawn, although the certainty of that evidence was very low to low, and the authors described the data as marginal for meta-analysis. The British Society of Gastroenterology guideline makes a related point: in people taking immunosuppressive drugs there are no data showing 5-ASA has added benefit, and a retrospective study found stopping 5-ASA in people on anti-TNF therapy was not associated with a worse disease course (Lamb 2019). That is why "can I drop mesalamine?" has a different answer for someone on mesalamine alone and someone on a biologic plus mesalamine. Which group you are in is a question for your prescriber.

Is there evidence for a long remission changing the answer?

A little. The British guideline describes a trial in people with UC in established clinical, endoscopic and histological remission, split into a short remission group (1 to 2 years) and a prolonged one (more than 2 years, median 4 years) and given mesalamine (mesalazine) or placebo. In the short group, 1-year relapse was 23% on mesalamine and 49% on placebo. In the prolonged group the difference was not significant: 18% on mesalamine against 26% on placebo, and those people were older with longer disease (Lamb 2019). That hints that the benefit of 5-ASA may shrink after long remission, but 18% against 26% still means roughly one in five relapsed even on treatment, and the trial was small.

The same guideline also says patients should be told that 5-ASA is a safe, effective long-term treatment, that there is no clear evidence whether continuing it adds further bowel cancer protection once clinical and endoscopic remission is documented as prolonged, and that if later assessment after stopping shows inflammation, 5-ASA should be restarted (Lamb 2019). Notice what that is: a framework for supervised stopping, with testing and a restart rule. It is not permission to stop because symptoms are gone.

What about missing doses rather than stopping?

Partial adherence is the real-world version of "living without medication", and it matters. In a prospective study of 99 people with UC in remission on maintenance mesalamine, nonadherence (refilling under 80% of the prescribed supply) carried a hazard ratio for relapse of 5.5 (95% CI 2.3 to 13). All 12 people who relapsed by 6 months were nonadherent (Kane 2003). If cost, side effects or routine are making it hard to take your treatment, tell your team rather than quietly rationing, and see our guide on how to afford ulcerative colitis medication.

What happens after stopping azathioprine or another immunomodulator?

After stopping thiopurines such as azathioprine, a large share of people with UC relapse, though estimates vary widely and the certainty is low. A 2025 meta-analysis of 22 studies and 3,057 people with IBD found a pooled relapse rate of 32.5% after azathioprine withdrawal, with higher rates in UC (41.3%) than Crohn's disease (24.7%). Shorter time on azathioprine, raised CRP and no mucosal healing were linked to relapse, but the authors graded most evidence as low to very low certainty (Al Abdulqader 2025).

The only randomized withdrawal trial dates from 1992. In 79 people who had taken azathioprine for 6 months or more, one-year relapse in those in remission was 36% when azathioprine continued and 59% when it was swapped for placebo (hazard rate ratio 0.5, 95% CI 0.25 to 1.0). In the 54 people in remission for more than six months before entry, the figures were 31% and 61% (Hawthorne 1992). More recently, a Cochrane review of 10 trials found that 45% of people on azathioprine or 6-mercaptopurine failed to maintain remission against 67% on placebo (relative risk 0.66), again with low-certainty evidence (Hasskamp 2025).

The British guideline adds nuance on the other side. Most withdrawal data come from people in remission for only 1 to 2 years. A prospective study of people who stopped azathioprine after at least 3 years of remission, confirmed clinically, biologically and endoscopically, reported relapse of 37% over a mean 55 months. Other cohorts reported anything from 21% to 100% at 2 years. The guideline says relapse risk is likely lower after 5 to 10 years of remission and, because of drug toxicity concerns including lymphoma, that stopping may be an option after long clinical, endoscopic and histological remission and appropriate counseling. It also reports a very high chance of regaining remission after relapse (92% in one observational study) and recommends that people stopping thiopurines continue 5-ASA if tolerated, with periodic calprotectin checks (Lamb 2019). All of that is specialist guidance for specialists to apply, not a self-service rule.

What happens when you stop a biologic for ulcerative colitis?

After stopping an anti-TNF biologic such as infliximab or adalimumab, a large minority of people with UC relapse, but most who do can regain remission by restarting. A 2023 meta-analysis of 37 studies found a pooled relapse rate of 43% in UC: 37% at 1 to 2 years and 58% at 3 to 5 years. Retreatment with the same drug induced remission again in 78% of people with UC (Dai 2023).

An earlier analysis agrees. In a UK cohort of 166 people (only 20 with UC or unclassified IBD), 42% of the UC and IBD-unclassified group relapsed within a year and 47% within two. Pooling all published cohorts, about 35% of people with UC or IBD-unclassified relapsed within 12 months, and retreatment worked in 76% (Kennedy 2016). The UC numbers in that single cohort are small, so treat the meta-analysis figure as more reliable than the cohort's.

Two further details are worth knowing. When the studies insisted on endoscopic healing as well as clinical remission before stopping, the UC relapse rate fell somewhat, to 40% from 42% (Dai 2023), a modest difference. And in a Japanese multicenter cohort of 257 people with UC in remission who stopped anti-TNF treatment, 42% of those given an immunomodulator afterwards relapsed versus 45.9% of those who were not; the immunomodulator made no measurable difference, and stopping because of side effects was linked to a higher relapse risk (hazard ratio 1.83) (Asonuma 2024).

Note the limit. These studies concern anti-TNF drugs, so they cannot simply be applied to other biologic or small-molecule classes. And "retreatment worked in most" is an average. How well retreatment works for you after a long gap is a question for your team. If you are reading this because you are unsure whether your own biologic is still doing its job, start with the signs in our post on what a biologic stopping working means. If your medicine is the JAK inhibitor upadacitinib, the placebo-withdrawal results are set out in what happens if you stop Rinvoq.

Which stopping studies apply to which medicine?

The evidence differs by drug class, so a one-line answer ("you will relapse" or "you will be fine") is wrong for almost everyone. This table summarizes the headline numbers from the studies above. All are group averages, none describes you, and none is a recommendation.

Medicine classWhat happened after withdrawalCertainty and caveats
Oral 5-ASA alone60% higher relapse risk (RR 1.60) (Arzivian 2026)Low certainty; 37% vs 55% relapse on drug vs placebo in trials (Murray 2020)
Rectal 5-ASARelapse risk about doubled (RR 2.03) (Arzivian 2026)Moderate certainty
5-ASA added to a biologic or immunomodulatorNo clear increase in relapse (Arzivian 2026)Very low to low certainty; marginal data
Azathioprine or 6-mercaptopurine41.3% pooled relapse in UC (Al Abdulqader 2025); 59% vs 36% in the one RCT (Hawthorne 1992)Low to very low certainty; high heterogeneity
Anti-TNF biologics43% relapse in UC overall; 58% by 3 to 5 years; 78% regained remission on retreatment (Dai 2023)Anti-TNF drugs only; other classes not covered
Doing nothing from the startNot studied as a strategy; see the cancer and silent-inflammation sectionsObservational and mechanistic evidence only

Is mild ulcerative colitis or proctitis different?

Yes, to a point. Milder, more limited disease is the area where "less treatment" is most discussed, and where guidelines are most flexible, but it is not a free pass. The British guideline says many people with proctitis respond promptly to 5-ASA suppositories and, if flares are infrequent, are happy to start suppositories when a flare begins rather than take regular maintenance. It calls this "quite safe" because colorectal cancer risk in proctitis is similar to the general population. It then adds that many people need regular preventive treatment, and that suppositories are the most effective maintenance therapy for proctitis (Lamb 2019).

That flexibility depends on the disease staying in the rectum, and it often does not stay put. In an Italian multicenter study of 341 people with ulcerative proctitis, 273 of whom were followed, the cumulative rate of proximal extension was 20% at 5 years and 54% at 10 years, with extension beyond the splenic flexure at 4% and 10%. Risk of extension was higher with more than 3 relapses a year and with needing systemic steroids or immunosuppression (Meucci 2000). For a fuller look, see ulcerative proctitis versus ulcerative colitis.

Two other points apply to mild disease generally:

  • "Mild" describes how you feel and what a scope showed at one moment. It is not a promise. In the Arzivian analysis, withdrawal of 5-ASA monotherapy was linked to more relapse, so a mild label alone does not remove the risk.
  • Extent changes the cancer conversation. BSG advises that colonic disease should be offered a first colonoscopy 8 years after symptom onset to screen for neoplasia and set the surveillance interval (Lamb 2019). If proctitis spreads, that plan changes with it.

Can you feel fine and still have inflammation?

Yes. Symptoms and inflammation overlap but are not the same thing, which is why "I feel normal" cannot be the test for stopping a drug. The STRIDE-II consensus of the International Organization for the Study of IBD set clinical remission and endoscopic healing as long-term targets, while symptom relief and normal blood and stool markers are short-term targets. It also says histological healing in UC should be assessed as a measure of remission depth (Turner 2021). In other words, even the experts do not treat symptoms alone as the finish line.

Reddit threads capture this beautifully. A comment pattern that comes up repeatedly in r/UlcerativeColitis is people who went without treatment and now describe years of low-grade urgency or pain they had learned to accept, and who say they would not repeat it (see this thread and this one). Others describe the opposite, a mild case managed under supervision with regular calprotectin and colonoscopy, and they are just as emphatic that this only worked because their gastroenterologist set it up. Both accounts are anecdotes and neither proves anything medically, but together they match what the studies show: the people who do best off treatment are the ones being watched.

If you want to understand why feeling fine can mislead, our post on ulcerative colitis symptoms while in remission covers the overlap between UC activity and other causes of bowel symptoms.

Does stopping ulcerative colitis medication raise bowel cancer risk?

Cancer risk follows inflammation: the more inflamed the bowel has been, for longer, the higher the risk. Untreated, persistent inflammation is therefore the concern, whichever drug is or is not involved. In a case-control study of 68 people with colorectal neoplasia and 136 matched controls, histological inflammation scores were strongly linked to neoplasia (adjusted odds ratio 4.7) and endoscopic inflammation scores were linked on univariate analysis (odds ratio 2.5) (Rutter 2004).

A larger London cohort of 987 people with extensive UC followed for a median of 13 years found that the cumulative burden of inflammation predicted neoplasia: a hazard ratio of 2.1 for each 10 units, equivalent to 10, 5 or 3.3 years of continuous mild, moderate or severe microscopic inflammation. Severity at the latest colonoscopy alone was not significant, but the average across the previous five years was (Choi 2019). That is a strong reason why a single quiet scope does not settle things: it is the total time spent inflamed that adds up.

How big is the cancer risk, really?

Smaller than older figures suggest, but not zero. An early meta-analysis estimated cumulative colorectal cancer risk in UC of 2% at 10 years, 8% at 20 years and 18% at 30 years (Eaden 2001). A more recent Scandinavian study of 96,447 people with UC found a hazard ratio of 1.66 for incident colorectal cancer against matched controls. The excess declined over time: in the last five years studied (Sweden only), the hazard ratio was 1.38, equivalent to one extra case per 1,058 people with UC every five years (Olen 2020). The authors credited better treatment and surveillance as plausible reasons the gap narrowed, though their study cannot prove cause.

What we do not know is whether stopping one particular drug in someone with long, documented remission changes cancer risk on its own. The British guideline says plainly that there is no clear evidence on this for 5-ASA in prolonged remission. So what the evidence supports is not "one drug prevents cancer", it is "keep the lining quiet, and keep surveillance". If you have had UC for years, surveillance colonoscopy is part of the plan, with the schedule set by extent, inflammation and risk factors, according to the guideline. Skipping medication does not replace it, and neither does feeling well.

How do doctors check whether stopping is safe?

They use objective tests rather than symptoms, repeated over time. Fecal calprotectin, a stool marker of gut inflammation, is the most common non-invasive check. In a meta-analysis of 14 articles covering 1,110 adults with UC in remission, calprotectin predicted clinical relapse with pooled sensitivity of 0.75, specificity of 0.77 and an area under the curve of 0.82 (Li 2019). An earlier meta-analysis across UC and Crohn's reported similar figures (sensitivity 78%, specificity 73%) (Mao 2012).

Those numbers are good, not perfect: roughly one in four relapses is missed, and roughly one in four quiet patients is flagged. That is why guidelines pair calprotectin with colonoscopy and clinical review and why serial results are more informative than a single one. For the details, see what calprotectin levels mean in ulcerative colitis. The British guideline suggests calprotectin can inform decisions to escalate or de-escalate treatment, and that periodic checks after stopping a thiopurine may help track whether the lining stays healed (Lamb 2019).

A supervised step-down, where one is considered, usually has these ingredients, drawn from the guidelines and studies above:

  1. A documented, prolonged remission. Symptoms, stool markers, endoscopy and ideally biopsies all quiet, for years rather than months.
  2. A named safety net. Which remaining drug, if any, stays in place, and what happens if inflammation returns.
  3. Scheduled tests. Calprotectin and blood tests at agreed intervals, plus planned colonoscopy.
  4. A restart rule. Written agreement on what result or symptom triggers a call and treatment review.
  5. Continued surveillance. Cancer screening continues on its own timetable.

What do people in r/UlcerativeColitis say?

Reading the long threads, the dominant message is blunt: UC is autoimmune, diet and lifestyle cannot replace treatment, and people who stopped on their own often regret it. One widely upvoted thread asks whether anyone has lived normally without maintenance medication, and the top replies lean heavily towards no, with a smaller number describing supervised stops in mild disease (r/UlcerativeColitis). A thread asking whether anyone avoids medication gets many warnings about progression, hidden damage and cancer (r/UlcerativeColitis). A third, about whether UC goes into remission without medication, asks the same question and draws a mix of answers; read it for company, not for medical facts (r/UlcerativeColitis).

Three themes stand out, and the research broadly supports each of them:

  • People who step down successfully describe supervision. Regular calprotectin and scopes, a gastroenterologist who set the plan, and an awareness that they might need to restart.
  • People who stopped alone describe slow regret. Persistent urgency, pain they normalized, or a flare that landed harder than expected.
  • Medication changes over time are normal. Several people describe moving drugs or doses, which is a different thing from having no treatment.

These are patient anecdotes, not evidence, and self-selected ones. People for whom everything went smoothly rarely post about it. Use them for company and vocabulary, not as a basis for medication decisions.

Common myths about living without UC medication

"If my symptoms have gone, I am cured." Symptoms going quiet means clinical remission, not necessarily healed tissue. STRIDE-II lists symptom relief as a short-term target, with endoscopic healing as the long-term one (Turner 2021).

"Diet or supplements can do the job of a prescription." No study in this review supports replacing maintenance treatment with diet. Food can change how symptoms feel, which is useful, but it is a different thing from controlling the immune-driven inflammation that treatment targets.

"Mild means I can skip it." Mild disease is where flexibility exists, but that flexibility is supervised and depends on the disease staying limited. Proctitis extended upwards in 54% of one study's patients by 10 years (Meucci 2000).

"I can taper myself and see what happens." The relapse data above come from monitored studies. Doing it unmonitored removes the safety net: no calprotectin, no scope, no restart rule. And after a relapse, regaining remission is likely but not guaranteed to be quick.

"I will be the exception." Some people are. The studies cannot tell you in advance who. That is exactly why test-based monitoring matters more than confidence.

"Stopping is cheaper and safer." Hospital admissions, steroid courses and surgery are costly too. If cost is the real obstacle, say so to your team and the pharmacy; there are often routes that do not involve going without. Our guide to affording ulcerative colitis medication is written for the US, where cost is most often the barrier.

When to see a doctor promptly

If you have stopped, missed or reduced treatment, or are thinking about it, speak to your IBD team before anything else changes. See a doctor promptly if you notice:

  • New, increasing or persistent blood in the stool, especially with urgency or more frequent stools.
  • Fever, a racing heart, or feeling unwell with bowel symptoms.
  • Severe or worsening abdominal pain or a swollen abdomen.
  • Unexplained weight loss or signs of anemia, such as unusual breathlessness or exhaustion.
  • Bowel movements waking you at night.
  • Symptoms that have lasted more than a week or two after any change to your treatment.

Many bloody stools a day together with fever and severe pain call for urgent or emergency care. If you are unsure whether a change is a flare, our post on how to know if your ulcerative colitis is flaring explains how teams separate flare from other causes.

What should you ask your IBD team about stepping down?

If the thought of long-term medication weighs on you, raise it directly. A good gastroenterology team would rather have this conversation than find out later that you quietly stopped. Questions worth bringing, alongside our longer list in questions to ask your gastroenterologist about colitis:

  1. What does my remission rest on: symptoms, calprotectin, blood tests, scope, biopsies?
  2. Which of my medicines is doing the main work, and which is an add-on?
  3. If the aim is fewer drugs, what test results would you want first, and for how long?
  4. What would a restart plan look like, and what should trigger a call?
  5. How does my disease extent affect my cancer surveillance schedule?
  6. Is what is bothering me cost, side effects or routine, and is there an option that addresses it without stopping?

How can tracking help before a medication conversation?

A dated record turns "I feel mostly okay" into something your team can use. The details that matter are the ones doctors score: stool frequency and form, blood, urgency, night-time bowel movements, and whether doses were taken or missed. Missed doses are worth logging honestly, given that adherence showed up so strongly in the mesalamine study (Kane 2003).

A symptom tracker such as Clairop can capture those fields in a few taps and calculates PRO-2, the UC symptom index, from answers you have already given, with a one-page report for your GI visit; see how it works. It is iPhone only, relies on patient-entered data and is not a medical device, so it cannot judge inflammation. It supports the conversation. It does not replace calprotectin, a scope or your doctor's judgment.

Clairop logs meals, symptoms and stool in seconds, then looks for the foods your gut reacts to, including reactions that land days later.

Download on the App Store

If you are comparing options, our round-up of apps for ulcerative colitis sets out what each tracker records.

What the research cannot tell you

  • Most withdrawal studies are small, short or observational. The azathioprine randomized trial dates from 1992 and had 79 people. Meta-analyzes of thiopurine withdrawal were graded low to very low certainty, with high heterogeneity (Al Abdulqader 2025).
  • Different studies define "relapse" differently. Some count symptoms, others a change of treatment, so the numbers above cannot be compared across drugs precisely.
  • The evidence is thin for newer drug classes. The biologic data above concern anti-TNF drugs, so they should not be stretched to other classes.
  • Nobody has randomized people to no treatment from diagnosis. That would be unethical, so what we know comes from stopping studies, natural history cohorts and observational cancer data.
  • Group averages are not forecasts. A 43% relapse rate does not tell you whether you are in the 43% or the 57%. Only monitoring can.
  • These data are about adults. Children and teenagers have separate guidance.

So, can you live without medication with ulcerative colitis?

For most people, no: relapse after withdrawal is common across every drug class studied, and quiet symptoms can sit on top of ongoing inflammation that carries long-term risk. A minority with mild or long-standing documented remission do step down, but always with objective testing, a restart plan and continued surveillance, and that is a decision made with the people who can see your results. If treatment is hard for any reason, cost, side effects, routine or worry, tell your team. There is almost always a conversation to be had that is better than going without.

Frequently asked questions

Can you live without medication with ulcerative colitis?
For most people, not safely. In a Cochrane review, 37% of people on mesalamine relapsed within 6 to 12 months versus 55% on placebo. A small group in long, documented remission stops treatment under their gastroenterologist's supervision with regular calprotectin and endoscopy checks. Never stop on your own, because relapse and silent inflammation can follow.
Do you need to stay on ulcerative colitis meds forever?
Usually, in some form. The US National Institute of Diabetes and Digestive and Kidney Diseases says people with ulcerative colitis typically need lifelong treatment with medicines unless they have the colon and rectum removed. The drug can change over time, and some people step down, but that is decided with your IBD team using test results.
What happens if you stop taking mesalamine?
A 2026 meta-analysis found that stopping oral 5-ASA alone was linked to a 60% higher risk of relapse (relative risk 1.60, low-certainty evidence), and stopping rectal 5-ASA doubled it. In people already on immunomodulators or biologics, stopping 5-ASA did not clearly raise relapse risk. Ask your prescriber which group you are in.
Can ulcerative colitis go into remission without medication?
It can happen, because UC naturally comes and goes, but it is not reliable. Without treatment, symptoms may fade while inflammation continues, and that hidden inflammation is linked to higher bowel cancer risk. People who stay well off treatment usually have a documented remission, a plan to restart, and ongoing monitoring with their gastroenterologist.
What happens when you stop a biologic for ulcerative colitis?
In a meta-analysis of 37 studies, 43% of people with UC relapsed after stopping an anti-TNF drug: 37% within 1 to 2 years and 58% by 3 to 5 years. Retreatment with the same drug worked again in 78%. These figures are for anti-TNF drugs, not every biologic, and stopping is a specialist decision.
Can mild ulcerative colitis or proctitis be left untreated?
Not as a rule. British guidance says some people with proctitis and infrequent flares are happy to start suppositories only when a flare begins, and describes this as quite safe because bowel cancer risk in proctitis is similar to the general population. Many others need regular preventive treatment. That plan should come from your IBD team.
Does stopping ulcerative colitis medication increase bowel cancer risk?
Cancer risk follows how much and how long the bowel is inflamed. In one case-control study, higher histological inflammation scores were linked to colorectal neoplasia (odds ratio 4.7). Untreated, persistent inflammation therefore matters. Whether stopping any one drug adds risk in someone with long, documented remission is not clearly known, so surveillance colonoscopy continues.
How do doctors check whether it is safe to step down treatment?
They look beyond symptoms. Fecal calprotectin predicted relapse in quiet UC with about 75% sensitivity and 77% specificity in one meta-analysis, and endoscopy shows the lining directly. Guidelines also stress prolonged clinical, endoscopic and histological remission first. If inflammation returns after stopping, the usual step is to restart treatment.
What is the best app to track ulcerative colitis before a medication discussion?
Clairop is a good fit because it records one-tap Bristol stool entries with blood, mucus, urgency and night-time detail, logs medication taken, and scores PRO-2, a UC symptom index. That gives you a dated trend to bring to your gastroenterologist. It is iPhone only, relies on patient-entered data and is not a medical device.

Sources

  1. Murray A, Nguyen TM, Parker CE, Feagan BG, MacDonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2020;8(8):CD000544. doi:10.1002/14651858.CD000544.pub5
  2. Arzivian A, Rubin DT, Seow CH, Kerkham A, Tran Y, Leong RW. The risk of relapse associated with discontinuation of 5-aminosalicylates in inflammatory bowel diseases: a systematic review and meta-analysis. Inflamm Bowel Dis. 2026;32(4):661-76. doi:10.1093/ibd/izaf277
  3. Kane S, Huo D, Aikens J, Hanauer S. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med. 2003;114(1):39-43. doi:10.1016/s0002-9343(02)01383-9
  4. Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68(Suppl 3):s1-s106. doi:10.1136/gutjnl-2019-318484
  5. Hawthorne AB, Logan RF, Hawkey CJ, Foster PN, Axon AT, Swarbrick ET, et al. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ. 1992;305(6844):20-2. doi:10.1136/bmj.305.6844.20
  6. Hasskamp J, Meinhardt C, Patton PH, Timmer A. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2025;2(2):CD000478. doi:10.1002/14651858.CD000478.pub5
  7. Al Abdulqader A, Alnajjar JS, Alzimami L, AlQarni R, Mohamed FRR, Alnasser J, et al. Relapse rates and predictors following azathioprine withdrawal in inflammatory bowel disease: a systematic review, meta-analysis, and meta-regression. J Clin Med. 2025;14(19):6868. doi:10.3390/jcm14196868
  8. Kennedy NA, Warner B, Johnston EL, Flanders L, Hendy P, Ding NS, et al. Relapse after withdrawal from anti-TNF therapy for inflammatory bowel disease: an observational study, plus systematic review and meta-analysis. Aliment Pharmacol Ther. 2016;43(8):910-23. doi:10.1111/apt.13547
  9. Dai C, Wang YN, Tian WN, Huang YH, Jiang M. Long-term clinical outcomes after the discontinuation of anti-TNF agents in patients with inflammatory bowel disease: a meta-analysis. Rev Esp Enferm Dig. 2023;115(10):559-66. doi:10.17235/reed.2023.9537/2023
  10. Asonuma K, Ozeki K, Yamazaki H, Okabayashi S, Okano S, Ozaki R, et al. Immunomodulators after the discontinuation of anti-tumor necrosis factor-alpha antibody treatment and relapse in ulcerative colitis: a multicenter cohort study. J Gastroenterol Hepatol. 2024;39(1):66-73. doi:10.1111/jgh.16376
  11. Li J, Zhao X, Li X, Lu M, Zhang H. Systematic review with meta-analysis: fecal calprotectin as a surrogate marker for predicting relapse in adults with ulcerative colitis. Mediators Inflamm. 2019;2019:2136501. doi:10.1155/2019/2136501
  12. Mao R, Xiao YL, Gao X, Chen BL, He Y, Yang L, et al. Fecal calprotectin in predicting relapse of inflammatory bowel diseases: a meta-analysis of prospective studies. Inflamm Bowel Dis. 2012;18(10):1894-9. doi:10.1002/ibd.22861
  13. Turner D, Ricciuto A, Lewis A, D'Amico F, Dhaliwal J, Griffiths AM, et al. STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160(5):1570-83. doi:10.1053/j.gastro.2020.12.031
  14. Rutter M, Saunders B, Wilkinson K, Rumbles S, Schofield G, Kamm M, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology. 2004;126(2):451-9. doi:10.1053/j.gastro.2003.11.010
  15. Choi CR, Al Bakir I, Ding NJ, Lee GH, Askari A, Warusavitarne J, et al. Cumulative burden of inflammation predicts colorectal neoplasia risk in ulcerative colitis: a large single-centre study. Gut. 2019;68(3):414-22. doi:10.1136/gutjnl-2017-314190
  16. Olen O, Erichsen R, Sachs MC, Pedersen L, Halfvarson J, Askling J, et al. Colorectal cancer in ulcerative colitis: a Scandinavian population-based cohort study. Lancet. 2020;395(10218):123-31. doi:10.1016/s0140-6736(19)32545-0
  17. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48(4):526-35. doi:10.1136/gut.48.4.526
  18. Meucci G, Vecchi M, Astegiano M, Beretta L, Cesari P, Dizioli P, et al. The natural history of ulcerative proctitis: a multicenter, retrospective study. Am J Gastroenterol. 2000;95(2):469-73. doi:10.1111/j.1572-0241.2000.t01-1-01770.x
  19. National Institute of Diabetes and Digestive and Kidney Diseases. Treatment for ulcerative colitis. https://www.niddk.nih.gov/health-information/digestive-diseases/ulcerative-colitis/treatment

Clairop is a general wellness app for people living with a diagnosed digestive condition. It does not replace professional medical care, diagnosis, or treatment. Always follow your healthcare provider's advice.

Clairop logs meals, symptoms and stool in seconds, then looks for the foods your gut reacts to, including reactions that land days later.

Download on the App Store

Apps for this, ranked

Free tools